Methods and compositions for the treatment of steatosis-associated disorders
US10940125B2 · kind B2 · utility
5Cited by
0References
10Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 16, 2016 |
| Grant date | Mar 9, 2021 |
| Priority date | — |
| Expiry date | Nov 5, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01076
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is directed to methods of treating a steatosis-associated disorder by administering a therapeutic agent selected from a lysosomal enzyme, an autophagy-inducing agent, or a combination thereof. Steatosis-associated disorders discussed herein include GSD la, GSD lb, GSD Ic, NAFLD, and NASH. Other embodiments are directed to methods of reversing steatosis, modulating autophagy, inducing autophagy, and reversing glycogen storage.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.